India Pharma Outlook Team | Saturday, 24 October 2026
Remibrutinib data from Novartis have brought renewed attention to the effectiveness of oral therapies for relapsing multiple sclerosis (MS), following the release of detailed Phase III trial results.
The REMODEL-1 and REMODEL-2 trials showed that remibrutinib reduced annualized relapse rates by 35.2 percent and 31.2 percent, respectively, compared with teriflunomide.
Although the reductions were statistically significant, they fell short of analysts’ expectations. The findings also indicated a potential benefit in delaying disability progression.
The findings also raise important questions about the relationship between relapse reduction and disability progression, how remibrutinib compares with other investigational treatments, and the effectiveness of oral therapies for multiple sclerosis.
The REMODEL trials met their primary endpoint by demonstrating significant reductions in annualized relapse rates. However, relapse control is only one measure of treatment effectiveness in multiple sclerosis.
MS can also cause disability to accumulate over time, even when patients experience fewer relapses. Consequently, researchers assess additional measures to understand whether a treatment can help preserve patients’ physical functioning.
Key findings from the combined trial data include:
These results suggest that remibrutinib’s potential benefits extend beyond relapse control, although the disability-progression findings require careful interpretation.
Also Read: 15 Pharma Marketing KPIs Indian Companies Should Track in 2026
Remibrutinib has also drawn attention because of its comparison with Roche’s experimental BTK inhibitor, fenebrutinib. Roche reported a 55 percent reduction in annualized relapse rates in pooled Phase III data, compared with teriflunomide.
However, the difference between these figures does not establish that fenebrutinib is definitively more effective than remibrutinib. Separate trials can differ in patient characteristics, study design, follow-up periods and statistical analysis.
A meaningful comparison should account for:
For pharmaceutical developers, these distinctions are important when interpreting competitive positioning.
Remibrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor designed to modulate immune pathways involved in MS-related inflammation. Its potential advantage is the possibility of controlling disease activity without chronic B-cell depletion.
Nevertheless, convenient administration alone does not establish a treatment’s clinical value. Oral MS therapies must demonstrate meaningful efficacy, an acceptable safety profile and sustained disease control.
The latest remibrutinib data provide evidence of relapse reduction and encouraging findings across additional disease measures.
Novartis also reported no liver safety signal in the trials, an important consideration given liver-related concerns associated with some BTK inhibitor programs.
Ultimately, the findings highlight the need to assess oral MS therapies through a combination of relapse prevention, disability outcomes, safety and long-term effectiveness rather than convenience or a single clinical endpoint.
.jpg)
